UnitedHealth Group Inc. (NYSE: UNH) reported third-quarter 2013 results before markets opened Thursday morning. The health insurance and benefits management firm posted diluted quarterly earnings per share (EPS) of $1.53 on revenues of $30.6 billion. In the same period a year ago, UnitedHealth reported EPS of $1.50 on $30.4 billion in revenue. Third-quarter results also compare to the consensus estimates for EPS of $1.53 on revenues of $30.78 billion.
The company cut its EPS outlook for the full year to a range of $5.40 to $5.50, just below the current consensus estimate of $5.51.
Enrollment growth year-to-date totals 4.35 million and includes gains in all major market categories. The consolidated medical care ratio rose 1.6% to 80.6% in the third quarter.
For the full year, the company forecasts revenues of $123 billion to $124 billion.
The company grew its Medicare and retirement revenues by 13% year-over-year to $11 billion in the quarter. The employer and individual insurance business slipped about 2.9% to $11.3 billion, and the company’s total Optum benefits management business grew 33% to $9.6 billion.
Shares were down more than 4% in the first 45 minutes of trading Thursday, at $72.10 in a 52-week range of $51.09 to $75.88. Thomson Reuters had a consensus analyst price target of around $79.30 before the results were announced.
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.